International Clinical Trial: A Randomized, Controlled, Open-label, Multicenter Phase II Study of Rellafup-a Plus Systemic Chemotherapy With or Without Intraperitoneal Chemotherapy as First-line Treatment for HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133373) titled 'A Randomized, Controlled, Open-label, Multicenter Phase II Study of Rellafup-a Plus Systemic Chemotherapy With or Without Intraperitoneal Chemotherapy as First-line Treatment for HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis' on Sept. 24.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The first hospital of China medical University

Condition: HER2-negative peritoneal metastatic gastric cancer / adenocarcinoma of the gastroesophageal junction

Intervention: Rilafuspa combined with chemotherapy and intraperitoneal infusion chemotherapy:Ril...